» Articles » PMID: 32375292

Liposomes Loaded with the Proteasome Inhibitor Z-Leucinyl-Leucinyl-Norleucinal Are Effective in Inducing Apoptosis in Colorectal Cancer Cell Lines

Overview
Date 2020 May 8
PMID 32375292
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is one of the main causes of cancer-related death in developed countries. Targeted therapies and conventional chemotherapeutics have been developed to help treat this type of aggressive cancer. Among these, the monoclonal antibodies cetuximab (Cxm) and panitumumab specifically target and inactivate the signaling of ERBB1 (EGF receptor), a key player in the development and progression of this cancer. Unfortunately, these antibodies are effective only on a small fraction of patients due to primary or secondary/acquired resistance. However, as ERBB1 cell surface expression is often maintained in resistant tumors, ERBB1 can be exploited as a target to deliver other drugs. Liposomes and immunoliposomes are under intensive investigation as pharmaceutical nanocarriers and can be functionalized with specific antibodies. In this study, we first investigated the anti-cancer activity of a cell permeable tripeptide, leucine-leucin-norleucinal (LLNle), an inhibitor of gamma-secretase and proteasome, in three different CRC cell lines that express ERBB1. We formulated LLNle-liposomes and Cxm-conjugated LLNle-loaded liposomes (LLNle-immunoliposomes) and evaluated their efficacy in inhibiting cell survival. Despite similar pro-apoptotic effects of free LLNle and LLNle-liposomes, immunoliposomes-LLNle were significantly less effective than their unconjugated counterparts. Indeed, immunoliposomes-LLNle were readily internalized and trafficked to lysosomes, where LLNle was likely trapped and/or inactivated. In conclusion, we demonstrated that LLNle was readily delivered to CRC cell lines by liposomes, but immunoliposomes-LLNle failed to show significant anti-cancer activity.

Citing Articles

Advancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine.

Izadiyan Z, Misran M, Kalantari K, Webster T, Kia P, Basrowi N Int J Nanomedicine. 2025; 20:1213-1262.

PMID: 39911259 PMC: 11794392. DOI: 10.2147/IJN.S488961.


An Updated Review on the Role of Nanoformulated Phytochemicals in Colorectal Cancer.

Das A, Adhikari S, Deka D, Baildya N, Sahare P, Banerjee A Medicina (Kaunas). 2023; 59(4).

PMID: 37109643 PMC: 10143464. DOI: 10.3390/medicina59040685.


Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review.

Cepero A, Luque C, Cabeza L, Perazzoli G, Quinonero F, Mesas C Int J Nanomedicine. 2022; 17:5065-5080.

PMID: 36345508 PMC: 9635983. DOI: 10.2147/IJN.S368814.


The Depolarization-Evoked, Ca-Dependent Release of Exosomes From Mouse Cortical Nerve Endings: New Insights Into Synaptic Transmission.

Olivero G, Cisani F, Marimpietri D, Di Paolo D, Gagliani M, Podesta M Front Pharmacol. 2021; 12:670158.

PMID: 34366842 PMC: 8339587. DOI: 10.3389/fphar.2021.670158.

References
1.
Zappacosta R, Aschi M, Ammazzalorso A, di Profio P, Fontana A, Siani G . Embedding calix[4]resorcinarenes in liposomes: Experimental and computational investigation of the effect of resorcinarene inclusion on liposome properties and stability. Biochim Biophys Acta Biomembr. 2019; 1861(6):1252-1259. DOI: 10.1016/j.bbamem.2019.04.010. View

2.
Colombo M, Rizzuto M, Pacini C, Pandolfi L, Bonizzi A, Truffi M . Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. Bioconjug Chem. 2018; 29(11):3817-3832. DOI: 10.1021/acs.bioconjchem.8b00667. View

3.
De Maria P, Filippone P, Fontana A, Gasbarri C, Siani G, Velluto D . Cardanol as a replacement for cholesterol into the lipid bilayer of POPC liposomes. Colloids Surf B Biointerfaces. 2004; 40(1):11-8. DOI: 10.1016/j.colsurfb.2004.09.007. View

4.
Gavazzoni M, Vizzardi E, Gorga E, Bonadei I, Rossi L, Belotti A . Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. Eur J Pharmacol. 2018; 828:80-88. DOI: 10.1016/j.ejphar.2018.03.022. View

5.
Takebe N, Nguyen D, Yang S . Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2013; 141(2):140-9. PMC: 3982918. DOI: 10.1016/j.pharmthera.2013.09.005. View